Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIc open-label single-arm study of sunitinib malate capsules in EGFR-mutant advanced or metastatic NSCLC
CTR20223110Phase 2Active
- Sponsor
- Suzhong Pharmaceutical Group
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in non-small cell lung cancer (NSCLC), sponsored by Suzhong Pharmaceutical Group. Started Apr 2023; status: active.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20223110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223110.